Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources

Ecopipam (EBS-101) for Tourette syndrome, pediatric patients

Teva Pharmaceuticals · NDA
FDA decision due
Late Q1 2027
Exact date not public

The FDA is expected to decide on Ecopipam for Tourette syndrome, pediatric patients in late Q1 2027, under an NDA from Teva Pharmaceuticals.

What the FDA is deciding on Ecopipam for Tourette syndrome

The FDA is reviewing Teva Pharmaceuticals' application to approve Ecopipam (EBS-101) for tourette syndrome, pediatric patients.

First-in-class oral dopamine D1 receptor antagonist under priority review with Orphan Drug designation for children and adolescents with Tourette syndrome, which Teva says affects about 100,000 US children. If approved, it would be the first new Tourette treatment in more than 10 years and the first new mechanism in more than 50 years; the three approved drugs (haloperidol, pimozide, aripiprazole) all block D2 receptors, and Teva says only 20-30% of patients stay on prescription treatment after 1 year.

In the 153-patient Phase 2b D1AMOND trial, ecopipam reduced tic severity on the YGTSS total tic score more than placebo at week 12; in the Phase 3 randomized withdrawal trial published in JAMA Neurology, pediatric responders kept on ecopipam had a 53% lower risk of relapse over 12 weeks than those switched to placebo.

Teva has disclosed only that the action date falls late in the first quarter of 2027.

What an approval or a rejection of Ecopipam would mean

An approval starts a second race rather than ending the first one: specialty pharmacy setup, insurance review, and patient assistance typically take weeks even when everything goes right. Our guide to the 90 days after a rare disease approval explains the timeline and the moves families can make on day 1.

A complete response letter would mean the FDA declined to approve in the application's current form. The letter describes what the FDA wants addressed, and the company then decides whether to resubmit, run more studies or stop. Either way, this page updates with the outcome and what it means.

Frequently asked questions

When will the FDA decide on Ecopipam?

Teva Pharmaceuticals expects a decision in late Q1 2027 but has not given an exact date.

Who disclosed it: Teva Pharmaceuticals. The FDA does not publish these dates.

Can it move: the FDA can act early, and a major amendment to the application can push the date back 3 months.

Source: Teva announcement

What is Ecopipam being reviewed for?

Teva Pharmaceuticals submitted an NDA for Ecopipam in Tourette syndrome, pediatric patients.

What to know: First-in-class oral dopamine D1 receptor antagonist under priority review with Orphan Drug designation for children and adolescents with Tourette syndrome, which Teva says affects about 100,000 US children. If approved, it would be the first new Tourette treatment in more than 10 years and the first new mechanism in more than 50 years; the three approved drugs (haloperidol, pimozide, aripiprazole) all block D2 receptors, and Teva says only 20-30% of patients stay on prescription treatment after 1 year. In the 153-patient Phase 2b D1AMOND trial, ecopipam reduced tic severity on the YGTSS total tic score more than placebo at week 12; in the Phase 3 randomized withdrawal trial published in JAMA Neurology, pediatric responders kept on ecopipam had a 53% lower risk of relapse over 12 weeks than those switched to placebo. Teva has disclosed only that the action date falls late in the first quarter of 2027.

How much will Ecopipam cost?

Teva Pharmaceuticals has not announced a price. Drugmakers usually set it around approval.

Help paying: drugmaker programs and charity funds usually open at launch.

Find help: the patient assistance finder lists programs by insurance type.

What happens after the Ecopipam decision?

This page updates with the outcome the day it is announced.

If approved: getting the drug still takes time. Specialty pharmacy setup, insurance review and patient assistance often take weeks. Our guide covers what families can do on day 1.

If not approved: a complete response letter means the FDA declined the application in its current form. Many are about manufacturing or how data were presented, and companies often resubmit.

Where this date comes from

The FDA does not publish PDUFA dates; companies disclose them. This one comes from Teva announcement. Dates can move, and the FDA can act early or late. This page rechecks against our calendar, which is re-verified daily.